Hester Biosciences Limited announced audited standalone earnings results for fourth quarter and full year ended March 31, 2018 and consolidated earnings for the full year ended March 31, 2018. For the quarter, on standalone basis, the company reported net sales/income from operations of INR 374.83 million, profit before tax of INR 94.41 million, profit for the period of INR 90.14 million or INR 10.59 per basic and diluted share compared to the net sales/income from operations of INR 355.96 million, profit before tax of INR 93.69 million, profit for the period of INR 71.10 million or INR 8.32 per basic and diluted share for the same quarter a year ago.

For the year, on standalone basis, on standalone basis, the company reported net sales/income from operations of INR 1,352.53 million, profit before tax of INR 437.07 million, profit for the period of INR 305.58 million or INR 35.92 per basic and diluted share compared to the net sales/income from operations of INR 1,255.79 million, profit before tax of INR 330.87 million, profit for the period of INR 249.40 million or INR 29.32 per basic and diluted share for the same quarter a year ago.

For the year, on consolidated basis, the company reported net sales/income from operations of INR 1,364.05 million, profit before tax of INR 361.21 million, profit for the period of INR 230.67 million or INR 27.12 per basic and diluted share compared to the net sales/income from operations of INR 1,254.03 million, profit before tax of INR 309.34 million, profit for the period of INR 227.87 million or INR 26.79 per basic and diluted share for the same quarter a year ago.

For the full year of 2019, the company expects tax rate would be the 25%.